An expanding body of literature has provided compelling evidence linking elevated levels of CDK1 to the prognosis of various malignant tumors, encompassing lung cancer [21], breast cancer [22], pancreatic cancer [23], cervical cancer [24] and colorectal cancer [25], ovarian cancer [26]. This evidence concerns the gene CDK1 and familial pancreatic carcinoma.